A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sanjeev Pathak, MD
Alkermes, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alkermes Investigational Site
Frankston, Victoria, Australia
- Alkermes Investigational Site
Noble Park, Victoria, Australia
- Alkermes Investigational Site
Richmond, Victoria, Australia
- Alkermes Investigational Site
San Juan, Puerto Rico
- Alkermes Investigational Site
San Juan, Puerto Rico
- Alkermes Investigational Site
Tucson, Arizona, United States
- Alkermes Investigational Site
Little Rock, Arkansas, United States
- Alkermes Investigational Site
Los Alamitos, California, United States
- Alkermes Investigational Site
Oceanside, California, United States
- Alkermes Investigational Site
Pico Rivera, California, United States
- Alkermes Investigational Site
Redlands, California, United States
- Alkermes Investigational Site
Santa Ana, California, United States
- Alkermes Investigational Site
Sherman Oaks, California, United States
- Alkermes Investigational Site
Temecula, California, United States
- Alkermes Investigative Site
Upland, California, United States
- Alkermes Investigational Site
Hollywood, Florida, United States
- Alkermes Investigational Site
Jacksonville, Florida, United States
- Alkermes Investigational Site
Lauderhill, Florida, United States
- Alkermes Investigational Site
Orlando, Florida, United States
- Alkermes Investigative Site
Palm Bay, Florida, United States
- Alkermes Investigational Site
Atlanta, Georgia, United States
- Alkermes Investigational Site
Decatur, Georgia, United States
- Alkermes Investigational Site
Pikesville, Maryland, United States
- Alkermes Investigational Site
O'Fallon, Missouri, United States
- Alkermes Investigational Site
Jamaica, New York, United States
- Alkermes Investigational Site
Mount Kisco, New York, United States
- Alkermes Investigational Site
Canton, Ohio, United States
- Alkermes Investigational Site
Cincinnati, Ohio, United States
- Alkermes Investigational Site
Oklahoma City, Oklahoma, United States
- Alkermes Investigational Site
Allentown, Pennsylvania, United States
- Alkermes Investigational Site
Memphis, Tennessee, United States
- Alkermes Investigational Site
Dallas, Texas, United States
- Alkermes Investigational Site
DeSoto, Texas, United States
- Alkermes Investigational Site
Woodstock, Vermont, United States
- Alkermes Investigative Site
Bellevue, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Jun 2017
- Primary completion
- 26 Feb 2020
- Completion
- 5 Mar 2020
- Last update posted
- 8 Apr 2021
- Registered enrollment
- 278
- Registry id
- NCT03188185
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.